Adaptyx Biosciences is building a wearable sensing platform that extends continuous monitoring beyond glucose, capturing small molecules, electrolytes, hormones, drugs, and proteins in real time. The system pairs its molecular data streams with AI-driven analytics to detect health trends early and prompt timely interventions. Initial application areas include heart-failure management, endocrine and fertility care, critical-care drug dosing, and personalized wellness. The company holds an exclusive license to IP generated over more than a decade of research at Stanford University and the Chan Zuckerberg Biohub. Current efforts focus on expanding the molecular switch pipeline, progressing clinical trials for the first indication, and scaling engineering, data-science, and clinical teams. Founded in 2022 and based in Menlo Park, California, Adaptyx’s technology remains investigational and has not yet entered commercial sales. To date, the company has secured $23 million in total funding, including the latest seed round.

Total raised

$14M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2025